Society of Robotic Surgeons 2026 Annual Meeting
Professor Stricker was a Keynote Speaker at the 2026 Society of Robotic Surgeons (SRS) Annual Meeting.
Society of Robotic Surgeons 2026 Annual Meeting Read More »
robotic surgery
Training Australian and New Zealand Urologists in Nanoknife
Professor Phillip Stricker conducted a series of training sessions at St Vincents Hospital in the use of Nanoknife.
Training Australian and New Zealand Urologists in Nanoknife Read More »
Golf Day in Support of the SVPCRC
The St Vincent’s Prostate Cancer Research Centre is celebrating the outstanding success of its recent charity golf day.
Golf Day in Support of the SVPCRC Read More »
NanoKnife Training for Doctors from the Asia Pacific Region
Professor Stricker performed the first two cases in NSW using St Vincent’s new Da Vinci Single Port Robot.
NanoKnife Training for Doctors from the Asia Pacific Region Read More »
Channel 7 News Story On Single Port Robotic Surgery
Jennifer Bechwati, National Health Editor for Channel 7, compiled a report on the Da Vinci Single Port surgical robot.
Channel 7 News Story On Single Port Robotic Surgery Read More »
First Da Vinci Single Port Robot Surgeries
Professor Stricker performed the first two cases in NSW using St Vincent’s new Da Vinci Single Port Robot.
First Da Vinci Single Port Robot Surgeries Read More »
USANZ Tasmanian Section Meeting 2025
Invited speaker on prostate cancer at the 2025 USANZ Tasmanian Section Meeting
USANZ Tasmanian Section Meeting 2025 Read More »
European Journal of Urology Editorial
Professor Stricker invited to produce the editorial for PRESERVE trial.
European Journal of Urology Editorial Read More »
Single Port Robot At St Vincent’s Hospital
Professor Phillip Stricker will be the first urologist in Australia to be trained on the new single-port robotic system.
Single Port Robot At St Vincent’s Hospital Read More »
Home
First and foremost I am a clinician and surgeon with a particular expertise and passion for the treatment of patients with prostate cancer and benign prostate conditions. I do this in three ways: firstly as your doctor or surgeon, secondly through the research I perform with my highly skilled team and thirdly by offering a comprehensive second opinion service. My
NanoKnife© IRE – UCLA Presentation
Prof Stricker presentaion on focal therapies at UCLA. Throughout October Prof Stricker was invited to give talks in America and Canada. At UCLA he presented a slideshow on focal therapies for prostate cancer with a deeper look at irreversible electroporation (IRE) and the NanoKnife procedure. The complete presentation can be seen here: Focal Therapies for
NanoKnife© IRE – UCLA Presentation Read More »
Focal Irreversible Electroporation
NanoKnife© IRE Results We have now treated 800 patients since February 2013. All patients have been meticulously followed up (100% follow up) with high-quality MRIs and biopsies, in addition to being offered validated quality of life questionnaires. Our current outcomes for focal irreversible electroporation in the primary setting (not after radiotherapy) is: Our Nanoknife publications can
Focal Irreversible Electroporation Read More »
Salvage Robotic Surgery Presentation At SRS
Professor Stricker was recently an invited presenter at the World Society of Robotic Surgery virtual conference (SRS Vitual Conference 2020) on salvage robotic surgery.
Salvage Robotic Surgery Presentation At SRS Read More »
Nanoknife – Focal Irreversible Electroporation (IRE)
Professor Stricker is currently the world’s most experienced focal nanoknife surgeon, having performed over 800 cases since 2013. He has modified and perfected his technique for select patients with prostate cancer. His nanoknife outcomes have been published in over 30 international peer reviewed papers. The most recent papers published in the British Journal of Urology International have
Nanoknife – Focal Irreversible Electroporation (IRE) Read More »
Focal Therapy
Focal therapy for selective patients with prostate cancer is a relatively new treatment for a select group of patients for the treatment of localised prostate cancer. The treatment is recommended for patients with localised prostate cancer stage T1 and T2 who are not candidates for prostatectomy because of their age, their general state of being